• Company
• The dilemma of price cuts for Lipiodol and Fattiodol
• by Nho, Byung Chul Apr 7, 2023 05:55am

• Company
• Rise of new drugs... subject of NA and public petitions
• by Eo, Yun-Ho Apr 7, 2023 05:54am

• Opinion
• [Reporter's View] Preferential price for innovative drugs
• by Lee, Jeong-Hwan Apr 6, 2023 05:54am

• Company
• LG Chem releases DPP-4+SGLT-2 combo Zemidapa Tab
• by Kim, Jin-Gu Apr 6, 2023 05:53am

• Company
• NeuroBo, a subsidiary of Dong-A ST, applies for NASH candida
• by Apr 6, 2023 05:53am

• Company
• Zuellig Pharma Korea turns profitable in 6 years
• by Apr 6, 2023 05:53am

• Company
• Onureg, PO acute leukemia drug, is scheduled to be proposed
• by Eo, Yun-Ho Apr 6, 2023 05:53am

• Policy
• Generics for Forxiga will be released simultaneously on the
• by Lee, Tak-Sun Apr 6, 2023 05:53am

• Company
• Patients and policy are trending in the pharma industry
• by Eo, Yun-Ho Apr 6, 2023 05:53am

• Policy
• Government's drug pricing policy
• by Lee, Jeong-Hwan Apr 5, 2023 05:48am